Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease.

[1]  Joe Y. Chang,et al.  Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2020, The Lancet. Respiratory medicine.

[2]  J. Welsh,et al.  Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma , 2020, Journal for ImmunoTherapy of Cancer.

[3]  B. Sander,et al.  A Cost-Utility Analysis of Atezolizumab in the Second-Line Treatment of Patients with Metastatic Bladder Cancer. , 2020, Current oncology.

[4]  Charles R. Thomas,et al.  Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. , 2020, European journal of cancer.

[5]  L. Dawson,et al.  Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity. , 2020, NPJ precision oncology.

[6]  Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer. , 2020, Immunotherapy.

[7]  J. Welsh,et al.  Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Yunzhu Li,et al.  Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. , 2020, Oral oncology.

[9]  A. Neugut,et al.  Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting , 2020, Journal of oncology.

[10]  S. C. Lee,et al.  Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer , 2020, BMC Health Services Research.

[11]  J. Welsh,et al.  Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiotherapy: A prospective-retrospective analysis of 3 phase I/II Trials. , 2020, International journal of radiation oncology, biology, physics.

[12]  Hongchao Li,et al.  First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer , 2020, American journal of clinical oncology.

[13]  Mark M. Davis,et al.  Comprehensive T cell repertoire characterization of non-small cell lung cancer , 2020, Nature Communications.

[14]  Tian-tian Zhang,et al.  Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC , 2020, Cancer medicine.

[15]  J. Welsh,et al.  Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials , 2020, Journal for ImmunoTherapy of Cancer.

[16]  R. Zhou,et al.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases , 2019, Nature Reviews Immunology.

[17]  Lingyu Li,et al.  First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China , 2019, Chinese medical journal.

[18]  Maureen B. Josephson,et al.  Clinical research study designs: The essentials , 2019, Pediatric investigation.

[19]  J. Marsh,et al.  An introduction to clinical trial design. , 2019, Paediatric respiratory reviews.

[20]  Chongqing Tan,et al.  First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis , 2019, Cancer.

[21]  J. Welsh,et al.  Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy , 2019, Journal of Immunotherapy for Cancer.

[22]  J. Aerts,et al.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[23]  S. Sakaguchi,et al.  Targeting Treg cells in cancer immunotherapy , 2019, European journal of immunology.

[24]  E. V. Van Allen,et al.  Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[25]  J. Lee,et al.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Kurachi.  CD8+ T cell exhaustion , 2019, Seminars in Immunopathology.

[27]  Frank X Liu,et al.  Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States. , 2019, Journal of managed care & specialty pharmacy.

[28]  R. Hollingsworth,et al.  Turning the corner on therapeutic cancer vaccines , 2019, npj Vaccines.

[29]  C. Caux,et al.  Cold Tumors: A Therapeutic Challenge for Immunotherapy , 2019, Front. Immunol..

[30]  J. Ioannidis,et al.  New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. , 2019, Cancer treatment reviews.

[31]  J. Wynne,et al.  Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation , 2018, Front. Oncol..

[32]  Joe Y. Chang,et al.  A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors , 2018, Journal of Immunotherapy for Cancer.

[33]  B. Gyawali,et al.  Duration of adjuvant immunotherapy—biologic, clinical and economic considerations , 2018, Medical Oncology.

[34]  Zhiyi Li,et al.  Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly. , 2018, American health & drug benefits.

[35]  R. Weichselbaum.  The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  F. Mennini,et al.  Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma , 2018, Clinical Drug Investigation.

[37]  W. Curran,et al.  T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient , 2018, Cancer Immunology, Immunotherapy.

[38]  J. Mauskopf,et al.  Direct costs associated with adverse events of systemic therapies for advanced melanoma , 2018, Medicine.

[39]  E. Jaffee,et al.  T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. , 2018, JCI insight.

[40]  James D. Murphy,et al.  Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2018, Journal of the National Cancer Institute.

[41]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[42]  T. Schumacher,et al.  T Cell Dysfunction in Cancer. , 2018, Cancer cell.

[43]  C. Simone,et al.  Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review , 2018, Journal of the National Cancer Institute.

[44]  Kelvin K. W. Chan,et al.  Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. , 2018, The oncologist.

[45]  Joe Y. Chang,et al.  Combining radiation plus immunotherapy to improve systemic immune response. , 2018, Journal of thoracic disease.

[46]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[47]  R. Emerson,et al.  Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells , 2017, Cancer Immunology Research.

[48]  S. Mallal,et al.  Cytomegalovirus (CMV) Epitope–Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects , 2017, The Journal of Immunology.

[49]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[50]  I. Saeterdal,et al.  Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting , 2017, BMJ Open.

[51]  K. Brock,et al.  Use of image registration and fusion algorithms and techniques in radiotherapy: Report of the AAPM Radiation Therapy Committee Task Group No. 132 , 2017, Medical physics.

[52]  Tianyu Zhao,et al.  Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. , 2016, International journal of radiation oncology, biology, physics.

[53]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[54]  J. Wolchok,et al.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  A. Harris,et al.  Imaging oligometastatic cancer before local treatment. , 2016, The Lancet. Oncology.

[56]  J. Klastersky,et al.  Side-effects of checkpoint inhibitor-based combination therapy , 2016, Current opinion in oncology.

[57]  O. Garrone,et al.  Immune-related response criteria: light and shadows , 2016, ESMO Open.

[58]  Juanita Lopez,et al.  Immuno-oncology combinations: raising the tail of the survival curve , 2016, Cancer biology & medicine.

[59]  S. P. Bilir,et al.  Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States. , 2016, American health & drug benefits.

[60]  M. Amonkar,et al.  Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries , 2016, Journal of medical economics.

[61]  M. Mehta,et al.  A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy , 2016, Cancer.

[62]  F. Garrido,et al.  The urgent need to recover MHC class I in cancers for effective immunotherapy , 2016, Current opinion in immunology.

[63]  L. Saltz.  Perspectives on Cost and Value in Cancer Care. , 2016, JAMA oncology.

[64]  B. Barber,et al.  Economic burden of toxicities associated with treating metastatic melanoma in eight countries , 2015, The European Journal of Health Economics.

[65]  B. Mirakhur,et al.  Economic burden associated with adverse events in patients with metastatic melanoma. , 2015, Journal of managed care & specialty pharmacy.

[66]  E. Klang,et al.  Target versus non-target lesions in determining disease progression: analysis of 545 patients , 2015, Cancer Imaging.

[67]  R. Weichselbaum,et al.  From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy , 2015, Clinical Cancer Research.

[68]  V. Schabert,et al.  Comparative healthcare costs in patients with metastatic melanoma in the USA , 2015, Melanoma research.

[69]  Vinay Prasad,et al.  Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. , 2015, JAMA oncology.

[70]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[71]  E. Berndt,et al.  Pricing in the Market for Anticancer Drugs , 2014, The journal of economic perspectives : a journal of the American Economic Association.

[72]  T. Fojo,et al.  Cancer drugs in the United States: Justum Pretium--the just price. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Scorsetti,et al.  Review and uses of stereotactic body radiation therapy for oligometastases. , 2012, The oncologist.

[74]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[75]  Caroline Dive,et al.  Circulating tumour cells: their utility in cancer management and predicting outcomes , 2010, Therapeutic advances in medical oncology.

[76]  Samuel Ryu,et al.  American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. , 2004, International journal of radiation oncology, biology, physics.

[77]  C. Melief,et al.  Identification of T-cell epitopes for cancer immunotherapy , 2007, Leukemia.

[78]  C. Huber,et al.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Robert D Timmerman,et al.  Stereotactic body radiation therapy. , 2004, Current problems in cancer.

[80]  S. Stevanović.  Identification of tumour-associated t-cell epitopes for vaccine development , 2002, Nature Reviews Cancer.

[81]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[82]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.